Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor–activating mutation-positive non–small-cell lung cancer patients in Hong Kong
Keyword(s):
Keyword(s):
2004 ◽
Vol 22
(14_suppl)
◽
pp. 7012-7012
◽
Keyword(s):
2004 ◽
Vol 22
(14_suppl)
◽
pp. 7012-7012
◽
Keyword(s):
2010 ◽
Vol 28
(15_suppl)
◽
pp. 7537-7537
◽
Keyword(s):
2014 ◽
Vol 32
(8)
◽
pp. 859-863
◽
2017 ◽
Vol 35
(6)
◽
pp. 692-692
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 7024-7024
◽